secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioNexus Gene Lab Corp (BGLC)
CIK:        0001737523
Form:       8-K
Filed at:   2026-03-17T23:59:59+00:00
Accession:  0001477932-26-001379
Event type: leadership
Sentiment:  positive
Materiality: 0.50
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioNexus Gene Lab appoints Dr. Muthu Meyyappan as CCO of Fidelion Diagnostics
-----------------------------------------------------------------------------

- Dr. Meyyappan appointed CCO of Fidelion effective March 11, 2026; will lead global commercial strategy for VitaGuard MRD platform.
- He brings 15+ years experience in oncology diagnostics, previously at Menarini, Congenica, Variantyx, and QIAGEN.
- BioNexus holds exclusive commercialization rights for VitaGuard in Southeast Asia through its Fidelion investment.
- MRD testing is a fast-growing precision oncology segment for early cancer recurrence detection.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737523/000147793226001379/0001477932-26-001379-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737523/000147793226001379/bglc_8k.htm
  HTML page:      https://secwatch.observer/filing/0001477932-26-001379

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer